Corrigendum: Interleukin-13 as a potential biomarker in the management of pediatric asthma – a longitudinal study

Authors

  • Prasanna Raju Department of Paediatrics, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, Tamilnadu, India https://orcid.org/0000-0002-4161-5904
  • Subash Sundar Department of Paediatrics, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, Tamilnadu, India https://orcid.org/0000-0002-6255-7125
  • Preethi Suresh Department of Paediatrics, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, Tamilnadu, India https://orcid.org/0009-0005-6373-6386
  • Leela Kakithakara Vajravelu Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur Campus, Chennai, Tamilnadu, India https://orcid.org/0000-0003-3288-1335
  • Vivekanandhan Aravindhan Department of Genetics, University of Madras, Chennai, India https://orcid.org/0000-0002-5639-4948

DOI:

https://doi.org/10.15584/ejcem.2025.2.29

Abstract

A Corrigendum on

Interleukin-13 as a potential biomarker in the management of pediatric asthma – a longitudinal study by Raju P, Sundar S, Suresh P, Vajravelu LK, Aravindhan V. Eur J Clin Exp Med. 2025;23(1):15–20. doi: 10.15584/ ejcem.2025.1.3.

Downloads

Download data is not yet available.

Downloads

Published

2025-06-30

How to Cite

Raju, P., Sundar, S., Suresh, P., Vajravelu, L. K., & Aravindhan, V. (2025). Corrigendum: Interleukin-13 as a potential biomarker in the management of pediatric asthma – a longitudinal study. European Journal of Clinical and Experimental Medicine, 23(2), 531. https://doi.org/10.15584/ejcem.2025.2.29

Issue

Vol. 23 No. 2 (2025)

Section

CORRIGENDUM

License

Copyright (c) 2025 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.